^
    Back
    Association details:
    Biomarker:BCR-ABL1 T315I
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Myeloid Leukemia)
    New
    Excerpt:
    Iclusig is a kinase inhibitor indicated for the:...Treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Chemotherapy
    Title:

    Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant

    Excerpt:
    We describe the case of a patient with a Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL)...Once the details of the T315I mutation were acquired, we initiated ponatinib treatment at a standard dosage and observed a rapid decrease of minimal residual disease (MRD) at molecular assessment.
    DOI:
    10.1159/000448750